Please try another search
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Michael D. Blaszyk | 72 | 2015 | Independent Director |
John Owen Brennan | 67 | 2021 | Independent Director |
Christobel E. Selecky | 69 | 2020 | Independent Director |
Richard Gerald Adcock | 55 | 2020 | President, CEO & Director |
Cheryl L. Cohen | 58 | 2019 | Lead Independent Director |
Linda Maxwell | 49 | 2021 | Independent Director |
Barry J. Simon | 59 | 2007 | Chief Corporate Affairs Officer & Director |
Wesley Kanne Clark | 80 | 2021 | Independent Director |
Patrick Soon-Shiong | 71 | 2014 | Executive Chairman of the Board and Global Chief Scientific & Medical Officer |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review